4195 — Genomics Bioscience & Technology Share Price
Last trade - 00:00- TWD1.17bn
- TWD1.58bn
- TWD708.38m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.76 | ||
| Price to Tang. Book | 1.78 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.63 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -12.61% | ||
| Return on Equity | -4.32% | ||
| Operating Margin | -18.03% | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | TWDm | 389.96 | 419 | 396.14 | 517.58 | 708.38 | n/a | n/a | 9.83% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +955.35 | +100.06 | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Genomics Bioscience & Technology Co Ltd is a Taiwan-based company principally engaged in the scientific research of genetic analysis. The Company mainly provides public gene sequencing and clinical sequencing services, which includes preventive genetic testing, primer synthesis and individualized medical and genetic screening for cancers. The Company is also involved in the manufacture and sales of biochemical instruments, reagents and consumables. The Company distributes its products in domestic market and to overseas markets.
Directors
- Last Annual
- December 31st, 2025
- Last Interim
- June 30th, 2026
- Incorporated
- October 16th, 2001
- Public Since
- December 16th, 2013
- No. of Employees
- 115
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Taiwan Stock Exchange
- Shares in Issue
- 80,000,057
- Address
- 14F, No.100 Section 1,, TAIPEI, 221
- Web
- https://www.genomics.com.tw/
- Phone
- +886 226961658
- Auditors
- Deloitte & Touche LLP
Upcoming Events for 4195
Similar to 4195
Abnova Taiwan
Taiwan Stock Exchange
Applied BioCode
Taiwan Stock Exchange
Energenesis Biomedical
Taiwan Stock Exchange
HanchorBio
Taiwan Stock Exchange
Kim Forest Enterprise
Taiwan Stock Exchange
FAQ
As of Today at 01:49 UTC, shares in Genomics Bioscience & Technology are trading at TWD14.60. This share price information is delayed by 15 minutes.
Shares in Genomics Bioscience & Technology last closed at TWD14.60 and the price had moved by -45.01% over the past 365 days. In terms of relative price strength the Genomics Bioscience & Technology share price has underperformed the FTSE Developed Asia Pacific Index by -59.12% over the past year.
There is no consensus recommendation for this security.
Find out moreGenomics Bioscience & Technology does not currently pay a dividend.
Genomics Bioscience & Technology does not currently pay a dividend.
Genomics Bioscience & Technology does not currently pay a dividend.
To buy shares in Genomics Bioscience & Technology you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of TWD14.60, shares in Genomics Bioscience & Technology had a market capitalisation of TWD1.17bn.
Here are the trading details for Genomics Bioscience & Technology:
- Country of listing: Taiwan
- Exchange: TAI
- Ticker Symbol: 4195
Based on an overall assessment of its quality, value and momentum Genomics Bioscience & Technology is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Genomics Bioscience & Technology. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -50.94%.
As of the last closing price of TWD14.60, shares in Genomics Bioscience & Technology were trading -27.43% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Genomics Bioscience & Technology PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at TWD14.60.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Genomics Bioscience & Technology's directors